CN103079549B - 具有结晶抑制保护膜的透皮治疗系统 - Google Patents

具有结晶抑制保护膜的透皮治疗系统 Download PDF

Info

Publication number
CN103079549B
CN103079549B CN201180042701.6A CN201180042701A CN103079549B CN 103079549 B CN103079549 B CN 103079549B CN 201180042701 A CN201180042701 A CN 201180042701A CN 103079549 B CN103079549 B CN 103079549B
Authority
CN
China
Prior art keywords
transdermal therapeutic
therapeutic system
gestodene
active component
pet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180042701.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103079549A (zh
Inventor
S·布拉赫特
I·泰赖拜希
T·朗古特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swiss Green Leaf Pharmaceutical Co ltd
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44653285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103079549(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of CN103079549A publication Critical patent/CN103079549A/zh
Application granted granted Critical
Publication of CN103079549B publication Critical patent/CN103079549B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180042701.6A 2010-09-06 2011-09-02 具有结晶抑制保护膜的透皮治疗系统 Expired - Fee Related CN103079549B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010040299A DE102010040299A1 (de) 2010-09-06 2010-09-06 Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
DE102010040299.0 2010-09-06
PCT/EP2011/065204 WO2012031985A1 (de) 2010-09-06 2011-09-02 Transdermale therapeutische systeme mit kristallisationsinhibierender schutzfolie (release liner)

Publications (2)

Publication Number Publication Date
CN103079549A CN103079549A (zh) 2013-05-01
CN103079549B true CN103079549B (zh) 2016-11-02

Family

ID=44653285

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180042701.6A Expired - Fee Related CN103079549B (zh) 2010-09-06 2011-09-02 具有结晶抑制保护膜的透皮治疗系统

Country Status (33)

Country Link
US (2) US8557279B2 (cg-RX-API-DMAC7.html)
EP (1) EP2613771A1 (cg-RX-API-DMAC7.html)
JP (2) JP6104800B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130114127A (cg-RX-API-DMAC7.html)
CN (1) CN103079549B (cg-RX-API-DMAC7.html)
AP (1) AP3586A (cg-RX-API-DMAC7.html)
AR (1) AR082907A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011298892B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013005305A2 (cg-RX-API-DMAC7.html)
CA (1) CA2810103C (cg-RX-API-DMAC7.html)
CL (1) CL2013000636A1 (cg-RX-API-DMAC7.html)
CO (1) CO6690753A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130098A (cg-RX-API-DMAC7.html)
CU (1) CU24172B1 (cg-RX-API-DMAC7.html)
DE (1) DE102010040299A1 (cg-RX-API-DMAC7.html)
DO (1) DOP2013000053A (cg-RX-API-DMAC7.html)
EA (1) EA032575B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012477A (cg-RX-API-DMAC7.html)
GT (1) GT201300062A (cg-RX-API-DMAC7.html)
IL (2) IL224980A (cg-RX-API-DMAC7.html)
MA (1) MA34581B1 (cg-RX-API-DMAC7.html)
MX (1) MX2013002602A (cg-RX-API-DMAC7.html)
MY (1) MY162768A (cg-RX-API-DMAC7.html)
NZ (1) NZ607630A (cg-RX-API-DMAC7.html)
PE (2) PE20131138A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500429A1 (cg-RX-API-DMAC7.html)
SG (2) SG187941A1 (cg-RX-API-DMAC7.html)
TN (1) TN2013000087A1 (cg-RX-API-DMAC7.html)
TW (1) TWI576245B (cg-RX-API-DMAC7.html)
UA (1) UA110217C2 (cg-RX-API-DMAC7.html)
UY (1) UY33590A (cg-RX-API-DMAC7.html)
WO (1) WO2012031985A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201301389B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1913878A (zh) * 2003-12-12 2007-02-14 舍林股份公司 无需渗透促进剂的激素透皮传递

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH674618A5 (cg-RX-API-DMAC7.html) 1987-04-02 1990-06-29 Ciba Geigy Ag
WO1990004397A1 (de) * 1988-10-27 1990-05-03 Schering Aktiengesellschaft Berlin Und Bergkamen Mittel zur transdermalen applikation enthaltend gestoden
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
EP0555360A1 (en) 1990-10-29 1993-08-18 Alza Corporation Transdermal contraceptive formulations, methods and devices
DE4210711A1 (de) 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
DE4405899A1 (de) * 1994-02-18 1995-08-24 Schering Ag Mittel zur transdermalen Applikation enthaltend Desogestrel
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
AU784196B2 (en) 1999-11-24 2006-02-23 Agile Therapeutics, Inc. Improved transdermal contraceptive delivery system and process
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
WO2002045701A2 (en) 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
EP1216699A1 (de) 2000-12-21 2002-06-26 Schering Aktiengesellschaft Transdermalsystem enthaltend ein hochpotentes Gestagen
US20030165547A1 (en) * 2001-05-18 2003-09-04 Elisabeth Picard-Lesboueyries Cosmetic uses of 3beta-acetoxy-7-oxo-DHEA
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
NZ541807A (en) * 2003-02-21 2009-07-31 Bayer Schering Pharma Ag UV stable transdermal therapeutic plaster
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
ES2596809T3 (es) * 2004-10-08 2017-01-12 Noven Pharmaceuticals, Inc. Dispositivo de administración transdérmica de fármacos que incluye un refuerzo oclusivo
DE102004062182B4 (de) 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
CA2739380C (en) * 2008-10-06 2014-12-09 Mylan Technologies, Inc. Amorphous rotigotine transdermal system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1913878A (zh) * 2003-12-12 2007-02-14 舍林股份公司 无需渗透促进剂的激素透皮传递

Also Published As

Publication number Publication date
CN103079549A (zh) 2013-05-01
UA110217C2 (en) 2015-12-10
ECSP13012477A (es) 2013-04-30
CR20130098A (es) 2013-05-15
SG10201506927TA (en) 2015-10-29
TW201217165A (en) 2012-05-01
CL2013000636A1 (es) 2013-09-13
JP2013536828A (ja) 2013-09-26
KR20130114127A (ko) 2013-10-16
JP6104800B2 (ja) 2017-03-29
CU20130031A7 (es) 2013-05-31
CU24172B1 (es) 2016-04-25
PE20180198A1 (es) 2018-01-26
CO6690753A2 (es) 2013-06-17
US9060955B2 (en) 2015-06-23
MA34581B1 (fr) 2013-10-02
SG187941A1 (en) 2013-04-30
JP2016216500A (ja) 2016-12-22
GT201300062A (es) 2015-01-16
US20140018751A1 (en) 2014-01-16
AP3586A (en) 2016-02-10
CA2810103C (en) 2019-06-18
AU2011298892B2 (en) 2015-03-12
AU2011298892A1 (en) 2013-03-28
AP2013006787A0 (en) 2013-04-30
IL251124B (en) 2020-07-30
EP2613771A1 (de) 2013-07-17
NZ607630A (en) 2015-02-27
MY162768A (en) 2017-07-14
TWI576245B (zh) 2017-04-01
WO2012031985A1 (de) 2012-03-15
UY33590A (es) 2011-10-31
PH12013500429A1 (en) 2019-10-07
US20120082714A1 (en) 2012-04-05
PE20131138A1 (es) 2013-10-26
US8557279B2 (en) 2013-10-15
EA032575B1 (ru) 2019-06-28
TN2013000087A1 (en) 2014-06-25
EA201390246A1 (ru) 2013-09-30
IL224980A (en) 2017-07-31
CA2810103A1 (en) 2012-03-15
IL251124A0 (en) 2017-04-30
DOP2013000053A (es) 2013-07-15
AR082907A1 (es) 2013-01-16
DE102010040299A1 (de) 2012-03-08
BR112013005305A2 (pt) 2016-08-16
MX2013002602A (es) 2013-04-08
ZA201301389B (en) 2021-05-26

Similar Documents

Publication Publication Date Title
US5676968A (en) Transdermal therapeutic systems with crystallization inhibitors
JP2543457B2 (ja) 経皮デバイス
TW537899B (en) Composition for the transdermal administration of steroid drugs
CA2120599C (en) Transdermal therapeutic systems containing crystallization inhibitors
US9682068B2 (en) Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders
JPH09505554A (ja) 低フラックスで経皮的な活性薬剤の送達システム
CZ2003890A3 (cs) Přípravek pro transdermální transport fentanylu
NZ502352A (en) Transdermal therapeutic system (TTS) for administering sexual steroid hormones
Rupal et al. Transdermal patches: an emerging mode of drug delivery system in pulmonary arterial hypertension
WO2021098791A1 (zh) 一种含有美金刚的透皮贴剂
JP5883459B2 (ja) ガランタミンまたはその塩を含む経皮送達システム
US9060955B2 (en) Transdermal therapeutic system with crystallization-inhibiting protective film (release liner)
JP2003104875A (ja) 放出遅延型薬物投与デバイス
AU2015203180B2 (en) Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
Kharia et al. Overview of Transdermal Medicated Patches with its research updates in preceding years.
US12318360B2 (en) Rivastigmine patch for long-term administration
HK1184696B (zh) 具有结晶抑制保护膜的透皮治疗系统
HK1184696A (en) Transdermal therapeutic systems with crystallization-inhibiting protective film
US20140370077A1 (en) Transdermal drug delivery system containing fentanyl
TW201311452A (zh) 具抑制結晶保護膜(離型襯墊)之經皮治療系統
JP2000514065A (ja) ドラッグデリバリーディバイスとその製造法
WO2014159778A1 (en) Transdermal drug delivery system containing fentanyl

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1184696

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1184696

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190730

Address after: Basel, Switzerland

Patentee after: Swiss Green Leaf Pharmaceutical Co.,Ltd.

Address before: German Monheim

Patentee before: BAYER INTELLECTUAL PROPERTY GmbH

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161102